This $2,881,950 Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) will fund the "Functional Connectivity Mechanisms of Opioid Abstinence" research project at Yale University from July 1, 2024 to April 30, 2029. The project aims to investigate neurological mechanisms underlying opioid use disorder (OUD) and treatment, with a focus on factors influencing relapse and treatment adherence for patients receiving medications...
This $4,801,857 federal Project Grant award, funded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to compare the effects of different medications for opioid use disorder (MOUD) on neuroinflammation and neurocognition in people living with HIV (PLWH). The goal is to evaluate whether opioid antagonist MOUD (e.g., XR-naltrexone) have anti-inflammatory and neuroprotective effects compared to opioid agonist MOUD...
This $1,370,628 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to investigate the mechanisms and regulators of kappa opioid receptor (KOR) signaling. The research at The Washington University, to be conducted from June 15, 2024 to March 31, 2029, seeks to identify the molecular pharmacology of KOR, with the goal of exploring alternative treatments for pain and related conditions. The study will define the...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $398,137 to Boston Interactome LLC to develop high-precision epigenetic therapeutics for opioid use disorder (OUD). The project aims to identify functional modulators of the neuronal G9A complex, which regulates DFosB expression during chronic opioid exposure, and biophysically characterize their drug-protein interactions. The efficacy...
This $159,711 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports a study titled "Electrophysiological Dynamics of Acute Opioid Use in Human Reward, Affect, and Pain Pathways." The project aims to investigate how acute opioid administration impacts neural connectivity within brain regions associated with opioid use disorder (OUD), including the amygdala, hippocampus, prefrontal cortex, and pain...
This $858,600 Project Grant was awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Pittsburgh. The grant aims to identify and validate G protein-coupled receptors (GPCRs) expressed by somatostatin-expressing inhibitory neurons in the prefrontal cortex that could be targeted for developing new treatments for opioid use disorder (OUD). The research will use an unbiased transcriptomics approach to identify...
This $601,612 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to investigate the role of the habenula-interpeduncular nucleus (IPN) circuit in the development of opioid tolerance and withdrawal. The project will use viral approaches, ribosome profiling, and calcium imaging in mice to examine gene expression changes and neuronal activity in the IPN in response to chronic oxycodone exposure. The...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), totaling $945,966 over the period of September 30, 2024 to July 31, 2029, will support research to unravel the neurobiological mechanisms by which the neuropeptide PEN and its receptor GPR83 interact with the mu-opioid receptor (MOR) in the periaqueductal gray (PAG) region of the brain. The goal is to determine if targeting the PEN-GPR83 pathway...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $772,800.00 to the University of Florida to conduct research aimed at identifying and pharmacologically targeting novel modulators of the mu-opioid receptor (MOR) signaling pathway. The overarching goal is to dissociate the beneficial analgesic effects of opioids from their harmful addictive properties by developing precision pharmacological...
This $419,876 Project Grant was awarded on September 15, 2024 by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant will support preclinical research to investigate the therapeutic potential of targeting the neuropeptide S (NPS) receptor to mitigate opioid addiction. Specifically, the grant aims to: 1) Determine if NPS receptor-targeted molecules can reduce oxycodone self-administration and motivation to obtain the drug in...